DKK 0.18
(-2.17%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 8.07 Million DKK | 2736171.19% |
2022 | 295.00 DKK | -100.0% |
2021 | 6.58 Million DKK | 0.0% |
2020 | - DKK | 0.0% |
2019 | - DKK | 0.0% |
2018 | - DKK | 0.0% |
2017 | - DKK | 0.0% |
2016 | - DKK | -100.0% |
2015 | 16.91 Million DKK | 0.0% |
2014 | - DKK | -100.0% |
2013 | 150.27 Million DKK | -35.67% |
2012 | 233.6 Million DKK | 24.48% |
2011 | 187.66 Million DKK | -22.19% |
2010 | 241.19 Million DKK | 2298.49% |
2009 | 10.05 Million DKK | 0.0% |
2008 | - DKK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 18.51 Million DKK | 16.85% |
2024 Q1 | 15.84 Million DKK | 102.11% |
2023 Q2 | 124 Thousand DKK | -44.14% |
2023 Q1 | 222 Thousand DKK | 75154.24% |
2023 Q3 | 1.05 Million DKK | 746.77% |
2023 FY | 8.07 Million DKK | 2736171.19% |
2023 Q4 | 8.07 Million DKK | 668.76% |
2022 Q2 | 6.74 Million DKK | 0.0% |
2022 FY | 295.00 DKK | -100.0% |
2022 Q4 | 295.00 DKK | 0.0% |
2021 FY | 6.58 Million DKK | 0.0% |
2021 Q4 | 6.58 Million DKK | 0.0% |
2021 Q2 | - DKK | 0.0% |
2020 Q4 | - DKK | 0.0% |
2020 FY | - DKK | 0.0% |
2020 Q2 | - DKK | 0.0% |
2019 Q4 | - DKK | 0.0% |
2019 Q2 | - DKK | 0.0% |
2019 FY | - DKK | 0.0% |
2018 Q4 | - DKK | 0.0% |
2018 FY | - DKK | 0.0% |
2018 Q2 | - DKK | 0.0% |
2017 Q2 | - DKK | 0.0% |
2017 FY | - DKK | 0.0% |
2017 Q4 | - DKK | 0.0% |
2016 Q2 | 16.91 Million DKK | 0.0% |
2016 FY | - DKK | -100.0% |
2016 Q1 | 16.91 Million DKK | 0.0% |
2015 Q2 | - DKK | 0.0% |
2015 Q4 | 16.91 Million DKK | 0.0% |
2015 Q1 | - DKK | 0.0% |
2015 FY | 16.91 Million DKK | 0.0% |
2015 Q3 | - DKK | 0.0% |
2014 Q4 | - DKK | 0.0% |
2014 Q3 | - DKK | 0.0% |
2014 FY | - DKK | -100.0% |
2014 Q1 | - DKK | -100.0% |
2014 Q2 | - DKK | 0.0% |
2013 Q2 | 191.46 Million DKK | -18.31% |
2013 FY | 150.27 Million DKK | -35.67% |
2013 Q3 | 191.72 Million DKK | 0.13% |
2013 Q4 | 150.27 Million DKK | -21.62% |
2013 Q1 | 234.39 Million DKK | 0.34% |
2012 Q3 | 233.43 Million DKK | -37.34% |
2012 FY | 233.6 Million DKK | 24.48% |
2012 Q4 | 233.6 Million DKK | 0.07% |
2012 Q1 | 387.24 Million DKK | 106.35% |
2012 Q2 | 372.51 Million DKK | -3.8% |
2011 Q2 | 349.56 Million DKK | -0.08% |
2011 FY | 187.66 Million DKK | -22.19% |
2011 Q3 | 225.25 Million DKK | -35.56% |
2011 Q4 | 187.66 Million DKK | -16.69% |
2011 Q1 | 349.83 Million DKK | 45.04% |
2010 FY | 241.19 Million DKK | 2298.49% |
2010 Q2 | 28 Million DKK | 0.0% |
2010 Q3 | 28.35 Million DKK | 1.26% |
2010 Q4 | 241.19 Million DKK | 750.5% |
2009 FY | 10.05 Million DKK | 0.0% |
2009 Q4 | 10.05 Million DKK | 0.0% |
2008 FY | - DKK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ALK-Abelló A/S | 439 Million DKK | 98.161% |
Bavarian Nordic A/S | 15.13 Million DKK | 46.667% |
Genmab A/S | 680 Million DKK | 98.813% |
Gubra A/S | 60.68 Million DKK | 86.699% |
Novo Nordisk A/S | 20.52 Billion DKK | 99.961% |
Orphazyme A/S | - DKK | -Infinity% |
Zealand Pharma A/S | 102.57 Million DKK | 92.131% |